A phase I trial of ZGN 1061 in patients with obesity
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2017
At a glance
- Drugs ZGN 1061 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Zafgen
- 10 Jun 2017 Results published in a Zafgen media release.
- 10 Jun 2017 According to a Zafgen media release, data from this trial was presented at the American Diabetes Association's 77th Annual Scientific Sessions (ADA).
- 06 Jun 2017 Results will be presented at the American Diabetes Association 77th Scientific Sessions 2017, according to a Zafgen media release.